Logo do repositório
 
Publicação

Public genomic cohort analyses reveal bcl6 expression as a prognostic marker in luminal a breast cancer

2025-11-21Documento de conferência Acesso embargado
Ver registo simples
datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorBarros, Patrícia
dc.contributor.authorGonçalves, Vânia
dc.contributor.authorJordan, Peter
dc.contributor.authorMatos, Paulo
dc.date.accessioned2026-03-04T12:19:03Z
dc.date.available2026-03-04T12:19:03Z
dc.date.issued2025-11-21
dc.description.abstractIntroduction: Breast cancer (BC) is the most common malignant neoplasm among women worldwide and remains a leading cause of cancer-related mortality. It is a heterogeneous disease classified into molecular subtypes with distinct prognostic and therapeutic implications. Luminal A is the most prevalent subtype, characterised by high expression of hormone receptors (oestrogen and progesterone), low proliferation rate, and generally favourable prognosis. However, consistent evidence indicates a significant risk of late recurrence and new neoplastic events, posing challenges for clinical follow-up strategies. Methodology: We analysed genomic data from the TCGA breast cancer cohort (n = 1247) to assess the prognostic value of the BCL6 gene, a transcriptional regulator previously implicated in tumour progression. Data on BCL6 expression, molecular subtyping (PAM50), and overall survival (OS) were retrieved. Results: Although BCL6 expression was globally reduced in tumours compared to normal tissue, it was significantly higher in Luminal A tumours than in other subtypes, with a subgroup (44%) maintaining expression levels similar to normal tissue. Importantly, within the Luminal A subtype, higher BCL6 expression was associated with poorer long term survival (p = 0.041). Discussion: These findings support the potential of BCL6 as a stratification biomarker for the risk of long term neoplasm recurrence within Luminal A breast cancer, with possible implications for tailoring the intensity and duration of clinical follow-up.por
dc.identifier.urihttp://hdl.handle.net/10400.18/11103
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBCL-6
dc.subjectluminal A
dc.subjectPrognostic Marker
dc.subjectBreast Cancer
dc.subjectVias de Transdução de Sinal e Patologias Associadas
dc.titlePublic genomic cohort analyses reveal bcl6 expression as a prognostic marker in luminal a breast cancereng
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2026-11-20
oaire.citation.conferencePlaceCoimbra, Portugal
oaire.citation.title29th Annual Meeting of the Portuguese Society of Human Genetics (SPGH), 20-22 novembro 2025
oaire.versionhttp://purl.org/coar/version/c_b1a7d7d4d402bcce

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Poster BCL6_SPGH2025.pdf
Tamanho:
1.03 MB
Formato:
Adobe Portable Document Format
Descrição:
poster
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DGH - Posters/abstracts em congressos internacionais